Clinical Trials Logo

Citation(s)

  •   Gao B, Gao W, Wan H, Xu F, Zhou R, Zhang X, Ji Q
    Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC). Diabetes Obes Metab. 2022 Feb 3. doi: 10.1111/dom.14661. [Epub ahead of print]

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study

Details for clinical trial NCT03794336